Suzanne A. Eccles

Overview

Best Publications

• Guidelines for the welfare and use of animals in cancer research

  P Workman;E O Aboagye;F Balkwill;A Balmain

  1567
  Citations

• Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

  Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  1554
  Citations

• A microRNA DNA methylation signature for human cancer metastasis

  Amaia Lujambio;George A. Calin;Alberto Villanueva;Santiago Ropero

  1316
  Citations

• Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

  Maria Vinci;Sharon M. Gowan;Frances E. Boxall;Lisa Jean Patterson

  1146
  Citations

• The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

  Adrian J. Folkes;Khatereh Ahmadi;Wendy K. Alderton;Sonia Alix

  1071
  Citations

• Metastasis: recent discoveries and novel treatment strategies

  Suzanne A Eccles;Danny R Welch

  956
  Citations

• NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

  Suzanne A Eccles;Andy Massey;Florence I Raynaud;Swee Y Sharp

  551
  Citations

• 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer

  Paul A. Brough;Wynne Aherne;Xavier Barril;Jenifer Borgognoni

  531
  Citations

• Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

  Suzanne A. Eccles;Eric O. Aboagye;Simak Ali;Annie S. Anderson

  523
  Citations

• Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

  Scott Wilkie;May C. I. van Schalkwyk;Steve Hobbs;David M. Davies

  509
  Citations

• Macrophage content of tumours in relation to metastatic spread and host immune reaction

  Suzanne A. Eccles;Peter Alexander

  509
  Citations

• Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

  Florence I. Raynaud;Suzanne Eccles;Paul A. Clarke;Angela Hayes

  460
  Citations

• The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

  Teeara Berry;William Luther;Namrata Bhatnagar;Yann Jamin

  355
  Citations

• Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer.

  P O-charoenrat;G Pillai;S Patel;C Fisher

  344
  Citations

• Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis

  Pornchai O-charoenrat;Pornchai O-charoenrat;Peter Rhys-Evans;Suzanne A. Eccles

  337
  Citations

• Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

  Florence I. Raynaud;Suzanne A. Eccles;Sonal Patel;Sonia Alix

  331
  Citations

• VEGF-A, VEGF-C, and VEGF-D in Colorectal Cancer Progression

  Mark L. George;Matthew G. Tutton;Frank Janssen;Abed Arnaout

  316
  Citations

• Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis

  Sharon Brader;Suzanne A Eccles

  304
  Citations

• Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer.

  M. L. George;A. S. K. Dzik‐Jurasz;A. R. Padhani;G. Brown

  303
  Citations

• Breast cancer metastasis: when, where, how?

  Suzanne A Eccles;Lenaic Paon

  14
  Citations